Page last updated: 2024-10-24

negative regulation of keratinocyte differentiation

Definition

Target type: biologicalprocess

Any process that stops, prevents, or reduces the frequency, rate or extent of keratinocyte differentiation. [GOC:go_curators]

Negative regulation of keratinocyte differentiation is a complex process that involves a cascade of molecular events, ultimately leading to the suppression of the transition of keratinocytes from a proliferative state to a differentiated state. This process is essential for maintaining epidermal homeostasis and preventing premature skin barrier formation. Here are the key molecular players and mechanisms involved:

1. **Transcriptional Regulation:**
- **Downregulation of Differentiation-inducing Transcription Factors:** Key transcription factors involved in keratinocyte differentiation, such as AP-1 (activator protein-1), C/EBP (CCAAT/enhancer binding protein), and p63, are negatively regulated. This can occur through direct binding of repressors, modifications to their DNA binding activity, or decreased expression of the transcription factor itself.
- **Upregulation of Repressor Proteins:** Repressor proteins, such as Id proteins (inhibitors of DNA binding) and Snail, can directly bind to the promoters of differentiation genes and inhibit their transcription.

2. **Signaling Pathway Modulation:**
- **Suppression of Wnt Signaling:** Wnt signaling pathway activation is essential for keratinocyte differentiation. Negative regulation involves inhibition of Wnt ligand production, inactivation of Wnt receptors (Frizzled), or disruption of downstream signaling components like β-catenin.
- **Activation of TGF-β Signaling:** Transforming growth factor beta (TGF-β) signaling can act as a negative regulator of keratinocyte differentiation by inducing the expression of inhibitors of differentiation, such as the inhibitor of differentiation (ID) genes.
- **Modulation of MAPK Pathways:** Mitogen-activated protein kinase (MAPK) pathways, such as the ERK pathway, can be activated to promote differentiation. Negative regulation can occur through the activation of inhibitory pathways or by the suppression of upstream activators of the MAPK pathway.

3. **Post-translational Modifications:**
- **Protein Degradation:** Differentiation-promoting proteins can be targeted for degradation by the ubiquitin-proteasome system. This mechanism ensures the removal of proteins essential for differentiation, thereby preventing premature differentiation.
- **Phosphorylation:** Phosphorylation events can regulate the activity and stability of key proteins involved in differentiation, often leading to their inactivation and inhibition of differentiation.

4. **Cellular Microenvironment:**
- **Cell-Cell Interactions:** The density of keratinocytes and their interactions with the extracellular matrix (ECM) can influence differentiation. Tight packing and strong interactions with ECM components can suppress differentiation.
- **Growth Factor Availability:** The presence or absence of growth factors, such as epidermal growth factor (EGF) and fibroblast growth factor (FGF), can regulate keratinocyte differentiation.

5. **Other Factors:**
- **MicroRNAs:** MicroRNAs (miRNAs) are small non-coding RNAs that can regulate gene expression. Several miRNAs have been identified as negative regulators of keratinocyte differentiation by targeting the mRNAs of differentiation-inducing genes.

The precise molecular mechanism of negative regulation of keratinocyte differentiation can vary depending on the specific context and the stimuli involved. However, the overarching principle is the suppression of the cellular program that drives keratinocytes to differentiate, thereby maintaining their proliferative potential and ensuring proper skin homeostasis.
'"

Proteins (2)

ProteinDefinitionTaxonomy
Histone-lysine N-methyltransferase EZH2A histone-lysine N-methyltransferase EZH2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q15910]Homo sapiens (human)
Serine/arginine-rich splicing factor 6A serine/arginine-rich splicing factor 6 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q13247]Homo sapiens (human)

Compounds (11)

CompoundDefinitionClassesRoles
3-deazaneplanocin3-deazaneplanocin: S-adenosylhomocysteine hydrolase antagonist
tanshinonetanshinone: from root of Salvia miltiorrhiza Bunge; RN given refers to tanshinone I; cardioprotective agent and neuroprotective agentabietane diterpenoidanticoronaviral agent
przewaquinone dprzewaquinone D: isolated from root of Salvia przewalskii; structure given in first source; RN given refers to the trans- isomer, przewaquinone D
tanshinone ii atashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first sourceabietane diterpenoid
s-adenosylhomocysteineS-adenosyl-L-homocysteine : An organic sulfide that is the S-adenosyl derivative of L-homocysteine.

S-Adenosylhomocysteine: 5'-S-(3-Amino-3-carboxypropyl)-5'-thioadenosine. Formed from S-adenosylmethionine after transmethylation reactions.
adenosines;
amino acid zwitterion;
homocysteine derivative;
homocysteines;
organic sulfide
cofactor;
EC 2.1.1.72 [site-specific DNA-methyltransferase (adenine-specific)] inhibitor;
EC 2.1.1.79 (cyclopropane-fatty-acyl-phospholipid synthase) inhibitor;
epitope;
fundamental metabolite
indacaterolindacaterol : A monohydroxyquinoline that consists of 5-[(1R)-2-amino-1-hydroxyethyl]-8-hydroxyquinolin-2-one having a 5,6-diethylindan-2-yl group attached to the amino function. Used as the maleate salt for treatment of chronic obstructive pulmonary disease.

indacaterol: a beta2 adrenoceptor agonist; indacaterol is the (R)-isomer; structure in first source
indanes;
monohydroxyquinoline;
quinolone;
secondary alcohol;
secondary amino compound
beta-adrenergic agonist;
bronchodilator agent
epz005687EPZ005687: inhibits EZH2 protein; structure in first sourceindazoles
epz-6438tazemetostat: a histone methyltransferase EZH2 inhibitor with antineoplastic activity
gsk-2816126GSK-2816126: inhibits EZH2 methyltransferase; structure in first sourcepiperazines;
pyridines
gsk343GSK343 : A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM).

GSK343: an EZH2 methyltransferase inhibitor
aminopyridine;
indazoles;
N-alkylpiperazine;
N-arylpiperazine;
pyridone;
secondary carboxamide
antineoplastic agent;
apoptosis inducer;
EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor
1-[(1R)-1-(1-ethylsulfonyl-4-piperidinyl)ethyl]-N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-3-indolecarboxamide(R)-1-(1-(1-(ethylsulfonyl)piperidin-4-yl)ethyl)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1H-indole-3-carboxamide: EZH2 inhibitorindolecarboxamide